Heparin indued thrombocytopenia, ITP, Multiple myeloma
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
I now have sufficient information to compose a comprehensive answer on all three topics. Let me now compile the final response.
Here is a comprehensive overview of all three conditions:
Heparin-Induced Thrombocytopenia (HIT)
Pathophysiology
HIT is an immune-mediated disorder, not a simple drug side effect. When heparin is given, it binds to platelet factor 4 (PF4) - a protein released from platelet alpha-granules. The PF4/heparin complex is immunogenic and triggers production of IgG antibodies against it.
These IgG antibodies then crosslink PF4/heparin complexes on the platelet surface, engaging FcγRIIA receptors, which causes:
- Platelet activation and aggregation
- Release of highly procoagulant platelet microparticles
- Paradoxical thromboembolism despite thrombocytopenia
This is why HIT is called a prothrombotic thrombocytopenia - the falling platelet count signals increased clotting risk, not bleeding risk. The combination with thrombosis is called HITT (HIT + thrombosis).
Type 1 vs. Type 2:
- Type 1 (non-immune): Mild, transient drop in platelets early after starting heparin. No clinical consequence. Resolves with continued therapy.
- Type 2 (immune): Begins 5-10 days after starting heparin. Immune-mediated, associated with thrombosis risk.
Clinical Assessment - The 4T Score
| Parameter | 2 Points | 1 Point | 0 Points |
|---|---|---|---|
| Thrombocytopenia | >50% fall + nadir ≥20k | 30-50% fall or nadir 10-19k | <30% fall or nadir <10k |
| Timing of fall | Days 5-10 / ≤day 1 if prior heparin | Beyond day 10, or timing unclear | ≤day 4 (no prior heparin) |
| Thrombosis | New confirmed thrombosis, skin necrosis | Progressive/recurrent thrombosis | None |
| Other Thrombocytopenia causes | None apparent | Possible other cause | Definite other cause |
- Score 0-3 = Low probability (0-3%) - testing not indicated
- Score 4-5 = Intermediate probability - test
- Score 6-8 = High probability (64%) - test + treat empirically
Laboratory Testing
-
PF4/heparin ELISA (immunoassay): High sensitivity (~98%) but lower specificity (~89%). Used as the initial screening test. Higher optical density values are more likely to be clinically significant.
- IgG-specific ELISA improves specificity with slight sensitivity loss
- Adding excess heparin (to block antibody binding) also improves specificity
-
Functional assays (confirmatory, high specificity):
- Serotonin Release Assay (SRA): Gold standard in North America - uses ¹⁴C-labeled serotonin uptake in washed platelets challenged with patient plasma at different heparin concentrations
- Heparin-induced platelet activation assay (HIPA): Comparable to SRA
- PF4-dependent P-selectin expression assay (PEA): Flow-based, in one study showed higher AUC than SRA (0.92 vs. 0.82)
Management
- Stop all heparin immediately (including LMWH flushes)
- Do NOT use LMWH as a substitute - anti-PF4/heparin IgG antibodies cross-react with LMWHs
- Start a non-heparin anticoagulant:
- Argatroban (direct thrombin inhibitor, IV): FDA-approved for HIT prophylaxis/treatment; starting dose 2 mcg/kg/min, monitor aPTT
- Bivalirudin (direct thrombin inhibitor): Also used effectively for HITT
- Fondaparinux (synthetic pentasaccharide): Least immunogenic glycosaminoglycan, does not cross-react with HIT antibodies in vivo; extremely rare cases of fondaparinux-induced thrombocytopenia reported
- Do NOT transfuse platelets (can fuel thrombosis)
- Warfarin should not be started until platelet count has recovered (risk of warfarin-induced skin necrosis and venous limb gangrene from protein C/S depletion)
Re-exposure to heparin: HIT antibodies usually disappear after 3 months. Re-challenge can be considered >6 months after antibody disappearance, with close monitoring.
Immune Thrombocytopenia (ITP)
Definition & Classification
ITP is an acquired autoimmune disorder characterized by autoantibodies directed against platelet surface antigens (commonly glycoproteins IIb/IIIa and Ib/IX), causing both:
- Accelerated platelet destruction by splenic macrophages
- Reduced platelet production (T-cell mediated megakaryocyte suppression)
Categories:
- Primary ITP: No identifiable trigger
- Secondary ITP: Associated with autoimmune diseases (SLE, RA), infections (HIV, HBV, HCV, EBV, varicella), malignancies (CLL, lymphoma)
- Drug-induced thrombocytopenia (DITP): Heparin is an important cause (see HIT above)
Temporal classification:
- Newly diagnosed: <3 months
- Persistent: 3-12 months
- Chronic: >12 months
- Severe: Platelet count <20,000/mm³
Pediatric vs. Adult ITP
| Feature | Pediatric | Adult |
|---|---|---|
| Age | 2-6 years | Any age (3x more common in women) |
| Onset | Acute, often post-viral (within 3 weeks) | Insidious, no prodrome |
| Typical platelet count | <20,000/mm³ | 30,000-100,000/mm³ |
| Course | Self-limited, >90% spontaneous remission | Chronic, relapsing |
| Symptoms | Sudden petechiae/purpura | Easy bruising, prolonged menses, mucosal bleeding |
Treatment (Adults)
| Platelet Count / Situation | Treatment |
|---|---|
| <30,000/mm³, asymptomatic or minor bleeding | Corticosteroids: Dexamethasone 40 mg PO/IV x 4 days (preferred) OR prednisone |
| <10,000/mm³ or significant bleeding | IVIG 1 g/kg (single dose) + corticosteroids; combination gives more sustained response |
| Pre-op / need rapid rise | IVIG + corticosteroids |
| Life-threatening bleeding, refractory to above | TPO receptor agonists: Eltrombopag or romiplostim (takes days-weeks to work) |
| Refractory/chronic ITP | Splenectomy (last resort) - removes major site of both antibody production and platelet destruction |
Note: Plasmapheresis and recombinant factor VIIa are no longer recommended. Rituximab (anti-CD20) is an alternative for refractory cases. Platelet transfusions have limited utility due to rapid destruction but may be used for life-threatening bleeds.
Pediatric: Children with newly diagnosed ITP and only skin manifestations can be managed with observation even with platelets <20,000/mm³, given high spontaneous remission rate.
Multiple Myeloma (MM)
Overview
Multiple myeloma is a malignant neoplasm of plasma cells (terminally differentiated B cells), typically arising in bone marrow. It is preceded by:
- MGUS (Monoclonal Gammopathy of Undetermined Significance) - present virtually universally before MM develops; may persist for up to 16 years before progression
- Smoldering Myeloma - middle ground: plasma cells 10-30% of marrow, M protein >3 g/dL, but asymptomatic; ~75% progress to MM over 15 years
Epidemiology:
- ~20,000 new cases/year in the US; incidence ~4.3/100,000
- Peak incidence: age 66-70 years; rare under 40
- Higher incidence in Black individuals; slightly earlier onset
- Median survival historically 3-4 years; newer agents are improving this; ~60% alive at 5 years
Pathophysiology
Genetic features:
- Rearrangements of the IGH locus (14q32) with various proto-oncogenes
- Cyclin D1/D3 rearrangements (cell cycle dysregulation)
- TP53 deletion (17p) - poor prognosis
- MYC rearrangements - plasma cell leukemia
- NF-κB pathway mutations - support B-cell survival
Cytogenetic prognostic groups:
- Favorable: Hyperdiploid (multiple trisomies of odd chromosomes); t(11;14); t(6;14)
- Unfavorable: Hypodiploid; del(13q14); t(4;14); t(14;16); del(17p13)/TP53 deletion
Key cytokine: IL-6 is the primary growth factor for myeloma cells (produced by tumor cells and marrow stromal cells). High IL-6 = poor prognosis.
Bone destruction: Myeloma cells secrete MIP1α (CCL3) which promotes osteoclast formation + inhibitors of the Wnt pathway that suppress osteoblasts → net bone resorption → hypercalcemia + pathologic fractures.
Morphology
- Bone lesions: "Punched-out" lytic defects (1-4 cm) on X-ray, most common in vertebral column, ribs, skull, pelvis, femur
- Marrow: Plasma cells >30% cellularity. May show:
- Flame cells - fiery red cytoplasm
- Mott cells - grapelike cytoplasmic droplets
- Russell bodies (cytoplasmic globules) / Dutcher bodies (nuclear)
- Plasmablasts or bizarre multinucleated forms
- Peripheral blood: Rouleaux formation (red cells stacking in linear arrays due to high immunoglobulin coating their surfaces)
- Immunophenotype: CD38+, CD138+, CD56+ (abnormal), CD19-, CD20-; monoclonal kappa or lambda light chains
CRAB Criteria (Diagnostic)
Diagnosis requires clonal plasma cells in marrow AND at least one CRAB criterion (or myeloma-defining event):
| Letter | Feature |
|---|---|
| C | Hypercalcemia (>11 mg/dL) |
| R | Renal insufficiency (creatinine >2 mg/dL or CrCl <40 mL/min) |
| A | Anemia (Hb <10 g/dL or >2 g below normal) |
| B | Bone lesions (≥1 lytic lesion on imaging) |
Additional myeloma-defining events (SLiM): clonal BM plasma cells ≥60%, serum FLC ratio ≥100, >1 focal lesion on MRI.
Laboratory Findings
- Serum protein electrophoresis (SPEP): M-spike (homogeneous band in γ or β region)
- Immunofixation: Characterizes M-protein isotype
- IgG: ~50-55% of cases
- IgA: ~20-25%
- Light chain only: ~20% (urine Bence Jones protein)
- IgD/IgE: rare
- Nonsecretory: ~1%
- Urine: Bence Jones proteins (free light chains) - cause "myeloma kidney" (cast nephropathy/tubular damage)
- Hyperviscosity syndrome: 7% of patients, usually IgA or IgG3
- Elevated ESR, elevated serum globulins
- Hypogammaglobulinemia in light-chain-only myeloma (increased infection risk)
- Amyloidosis in ~10-15% of MM (can contribute to renal failure)
Treatment
| Agent Class | Examples | Mechanism |
|---|---|---|
| Proteasome inhibitors | Bortezomib (Velcade), carfilzomib | Block protein degradation → accumulation of misfolded Ig → apoptosis |
| Immunomodulatory drugs (IMiDs) | Thalidomide, lenalidomide, pomalidomide | Redirect ubiquitin ligases to degrade pro-myeloma proteins |
| Alkylating agents | Melphalan (Alkeran), cyclophosphamide | DNA cross-linking |
| Corticosteroids | Dexamethasone | Anti-tumor, anti-inflammatory |
| Bisphosphonates | Zoledronic acid, pamidronate | Inhibit bone resorption; reduce fractures + hypercalcemia |
| Monoclonal antibodies | Daratumumab (anti-CD38), elotuzumab | Direct tumor killing + immune modulation |
| CAR-T cell therapy | Idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel | Targets BCMA (B-cell maturation antigen) on plasma cells; produces deep remissions but risks cytokine release syndrome, neurotoxicity |
| Autologous SCT | High-dose melphalan conditioning | Prolongs survival, not curative |
Quick Comparison Summary
| Feature | HIT | ITP | Multiple Myeloma |
|---|---|---|---|
| Cell type | Platelets (autoantibody-mediated destruction + activation) | Platelets (autoantibody-mediated destruction + reduced production) | Plasma cells (malignant clonal proliferation) |
| Antibody target | PF4/heparin complex (IgG) | Platelet surface glycoproteins (GPIIb/IIIa, GPIb/IX) | Monoclonal immunoglobulin (paraprotein) |
| Key risk | Thrombosis (paradoxical) | Bleeding | Bone destruction, renal failure, infection, hypercalcemia |
| Key test | PF4/heparin ELISA + SRA; 4T score | Diagnosis of exclusion; antiplatelet antibody testing | SPEP/UPEP, bone marrow biopsy, CRAB criteria |
| First-line Rx | Stop heparin; start argatroban/bivalirudin | Corticosteroids ± IVIG | Bortezomib + lenalidomide + dexamethasone (VRd) ± auto-SCT |
Sources: Henry's Clinical Diagnosis and Management by Laboratory Methods | ROSEN's Emergency Medicine | Robbins, Cotran & Kumar Pathologic Basis of Disease | Textbook of Family Medicine 9e | Goodman & Gilman's Pharmacological Basis of Therapeutics
This is a shared conversation. Sign in to Orris to start your own chat.